MIA-COMPNCT07758140
Comparative Self-collection for Cervical Cancer Screening Pivotal Study
At risk: Primary completion moved at least 3 months later, primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 14 words
- Primary and study completion dates pushed to Dec 2026
- Site details revised at 1 of 11 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Arms and interventions
1. Participants are 25 to 65 years of age and willing to provide informed consent. 2. Participants have an intact cervix.
1. Participants are 25 to 65 years of age and willing to provide informed consent. 2. Participants have an intact cervix. 3. One or more of: prior diagnosis of hrHPV within previous 6 months; abnormal cervical Pap cytology result of HSIL or higher (HSIL, AIS, or invasive carcinoma per the Bethesda 2014 system) within previous 6 months; and/or presenting for colposcopy/LEEP/excisional intervention.
Diagnostic tests: Mia by XytoTest, Rovers Cervex-Brush
Sites
11 sites in 1 country